Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016020332 - BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA

Publication Number WO/2016/020332
Publication Date 11.02.2016
International Application No. PCT/EP2015/067841
International Filing Date 03.08.2015
IPC
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
C07K 16/46 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
C07K 16/2809
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2809against the T-cell receptor (TcR)-CD3 complex
C07K 16/2878
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2878against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
C07K 16/3061
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
3061Blood cells
C07K 16/468
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
Applicants
  • ENGMAB AG [CH]/[CH]
Inventors
  • VU, Minh, Diem
  • STREIN, Klaus
  • AST, Oliver
  • BACAC, Marina
  • HANISCH, Lydia, Jasmin
  • FAUTI, Tanja
  • FREIMOSER-GRUNDSCHOBER, Anne
  • HOSSE, Ralf
  • KLEIN, Christian
  • MOESSNER, Ekkehard
  • MOSER, Samuel
  • MURR, Ramona
  • UMANA, Pablo
  • JUNG-IMHOF, Sabine
  • KLOSTERMANN, Stefan
  • MOLHOJ, Michael
  • REGULA, Joerg
  • SCHAEFER, Wolfgang
Agents
  • MILLER, David James
Priority Data
14179705.004.08.2014EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BISPECIFIC ANTIBODIES AGAINST CD3EPSILON AND BCMA
(FR) ANTICORPS BISPÉCIFIQUES ANTI CD3EPSILON ET BCMA
Abstract
(EN)
A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3epsilon, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the mino acid at position 213 is substituted independently by glutamic acid (E), r aspartic acid (D) (numbering according to Kabat). Also the manufacture and use of said antibody.
(FR)
La présente invention concerne un anticorps bispécifique bi- ou trivalent se liant spécifiquement aux deux cibles que sont le domaine extracellulaire de l'antigène de maturation des lymphocytes B humain (BCMA) et la CD3epsilon humaine, où les domaines variables VL et VH dans une chaîne légère et la chaîne lourde respective sont remplacés les uns par les autres, caractérisé en ce qu'il comprend un domaine constant CL dans lequel l'acide aminé à la position 124 est remplacé indépendamment par la lysine (K), l'arginine (R) ou l'histidine (H) (numérotation selon Kabat), et dans le domaine constant respectif CH1 l'acide aminé à la position 147 et l'acide aminé en position 213 est remplacé indépendamment par l'acide glutamique (E), ou l'acide aspartique (D) (numérotation selon Kabat) L'invention concerne également la fabrication et l'utilisation dudit anticorps.
Latest bibliographic data on file with the International Bureau